Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of COVAXIN™ in the US Market.
Definitive Agreement provides details of the previously announced intent to co-develop COVAXIN™ for the US market.
Ocugen and Bharat Biotech to share US commercialization profits.
Ocugen to receive initial supply of COVAXIN™ doses from...
* This is not financial advice. This is my non-expert opinion. *
Vistagen ( NASDAQ:VTGN ) is a clinical stage biopharmaceutical company with long-term potential. I believe it's technology is similarly game-changing the way I believe NanoFlu for Novavax is (www.novavax.com) ( ). It could have positive outcomes for the world. I hope that their tech comes to...
JUST GOT POSITIVE EU RECOMMENDATION
$AIM (old $HEB) granted EU Orphan Drug Designation for Rintatolimod for treatment of pancreatic cancer, Hemispherx Biopharma Europe.
Rintatolimod is Ampligen
This is going to trap shorts and when they PR this is going to explode!
www.ema.europa.eu
23andMe to Merge with Virgin Group's VG Acquisition Corp. to Become Publicly-Traded Company Set to Revolutionize Personalized Healthcare and Therapeutic Development through Human Genetics.
- 23andMe is a leading consumer genetics and research company that offers a personalized health and wellness experience, and has built a premier genetic database to unlock...
Sympathy play
Anavex stock gained after favorable data from Cassava Sciences in Alzheimer’s! With a rise yesterday, Cassava Sciences extended its gains after announcement of favorable data from an open-label study in Alzheimer’s disease!
The shares have been on a bullish mode for the last several days, reaching an all-time high, on encouraging data for its...
“Strong Buy” Penny Stock With Over 200% Upside on the Horizon
a biotechnology company with a focus on the treatment of glioblastomas, a class of aggressive tumors that attack the braid and spinal cord. These cancers, while rare, are almost always terminal, and CNS is working a new therapy designed to more effectively cross the blood-brain barrier to attack...
Lexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering
Lexaria also announced the pricing of an underwritten public offering (the "Offering") of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of...
TYME Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections
TYME announced that it has received notification that the United States Patent and Trademark Office has granted additional patent claims related to the Company’s metabolomic technology platform. The patent, U.S. Patent No. 10,905,698, is directed to methods for treating...
Will Argenx be Wall streets next Biotech unicorn? I am extremely bullish!
Biotech is booming business. Monoclonal antibodies are revolutionizing pharma industry.
Again great news for Argenx.
01feb2021
launches new global offering to raise funds after 'Go' decisions for CIDP treatment trials
www.argenx.com
www.argenx.com
02feb2021
Argenx raises $1 bln
...
Why SELLAS Life Sciences Is Surging Premarket?
SELLAS Life Sciences is captivating investors thanks to its late-stage cancer vaccine
Thanks to some news in December in the biopharma space, SLS stock is racing higher. So what was that news? And what else do you need to know?
its leading candidate Galinpepimut-S is making its way through Phase 3.
This...
Moleculin Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model
a preclinical study in animals demonstrated a potentially significant therapeutic benefit of Annamycin against metastatic osteosarcoma.
Computerized tomography (CT) scans demonstrated that animals treated with Annamycin exhibited significant suppression of tumor growth and...
Annovis Bio's Lead Candidate ANVS401 Improves Cognitive and Functional Outcomes in Stroke Mice Study
data showing that a combination treatment using the Company's lead candidate ANVS401 and pifithrin after stroke improved mice locomotor activity and cognitive function more so than treatment with just one or the other agent.
While both treatments yielded...
Cassava Sciences’ Simufilam Improves Cognition and Behavior in Alzheimer’s Disease in Interim Analysis of Open-label Study
- Patients’ Cognition Improved 1.6 Points on ADAS-Cog11 -a 10% mean improvement from baseline to month 6.
- Patients’ Behavior Improved 1.3 Points on NPI, a 29% mean improvement from baseline to month 6.
- Improvements Maintained at 6...
OTC name in the cutting-edge field of medical psilocybin is back in the consolidation zone. Can accumulate shares here or wait for the breakout confirmation to play to recent highs.
After GameStop's spectacular short squeeze, investors are now wondering if other heavily shorted stocks that are popular among contrarian Reddit investors, such as CEL-SCI.
As it turns out, discipline becomes paramount when the value of one's holdings goes up so high and so fast.
CEL-SCI is a development-stage biotech that is seeking to develop a novel...
The company’s development pipeline features drug candidates under investigation as treatments for short bowel syndrome (SBS) and celiac disease (CeD), two conditions that are both dangerous and difficult to treat.
9 Meters’ flagship product, Larazotide, is in Phase 3 development for the treatment of CeD. CeD affects about 1% of the population, yet there are no...
